Key Financial Figures (Consolidated) - Q1 FY27

Profitability:

  • Net Revenue from Operations: ₹1,045.08 Cr, up 44% YoY and 11% QoQ.
  • Operating EBITDA: ₹357.07 Cr, up 73% YoY and 11% QoQ.
  • Operating EBITDA Margin: 34.2%, expanded by 566 bps YoY but declined 8 bps QoQ.
  • Operating PBT: ₹283.27 Cr, up 101% YoY and 13% QoQ.
  • Operating PBT Margin: 27.1%, expanded by 764 bps YoY and 34 bps QoQ.
  • Profit After Tax (PAT): ₹243.31 Cr, up 108% YoY and 14% QoQ.
  • Total Comprehensive Income: ₹243.54 Cr, up 107% YoY.

Expense Breakdown:

  • Raw Material Cost: ₹449.75 Cr
  • Employee Expenses: ₹86.57 Cr
  • Other Expenses: ₹151.69 Cr
  • Interest Expenses: ₹32.12 Cr
  • Depreciation: ₹41.68 Cr
  • Tax: ₹75.05 Cr

Other Income and Items:

  • Other Income: ₹35.09 Cr
  • Exceptional Item: ₹0.00 Cr (compared to ₹13.72 Cr expense in Q4 FY26)

Key Financial Figures (Standalone) - Q1 FY27

Profitability:

  • Net Revenue from Operations: ₹694.68 Cr, up 28% YoY and 11% QoQ.
  • Operating EBITDA: ₹244.98 Cr, up 59% YoY and 33% QoQ.
  • Operating EBITDA Margin: 35.3%, expanded by 686 bps YoY and 597 bps QoQ.
  • Operating PBT: ₹219.00 Cr, up 63% YoY and 38% QoQ.
  • Operating PBT Margin: 31.5%, expanded by 674 bps YoY and 624 bps QoQ.
  • Profit After Tax (PAT): ₹190.64 Cr, up 69% YoY and 41% QoQ.
  • Total Comprehensive Income: ₹190.91 Cr, up 71% YoY.

Expense Breakdown:

  • Raw Material Cost: ₹292.40 Cr
  • Employee Expenses: ₹62.43 Cr
  • Other Expenses: ₹94.87 Cr
  • Interest Expenses: ₹4.88 Cr
  • Tax: ₹64.20 Cr

Business Vertical Performance

High Performance Products (HPP):

  • YoY Revenue Growth: 33%
  • Revenue growth driven by volume and higher realizations
  • Constructive pricing environment for HFCs with increasing interest for contractual offtakes
  • AHF facility commenced operations in Q4 FY26 and continues ramping up

Specialty Chemicals:

  • YoY Revenue Growth: 48%
  • Sustained growth with strong order visibility
  • Strong product pipeline with meaningful scale-up across existing molecules and new launches

Contract Development and Manufacturing Organization (CDMO):

  • YoY Revenue Growth: 82%
  • Strong momentum backed by order book
  • Continued deeper engagement with European CDMO major
  • Geographic Mix: Not specified in percentages

Ongoing Capex Program Details

| Project | Details | Capex | Funding | Completion | Revenue Potential |

| HFC Capacity Expansion | Additional capacity equivalent to 15,000 MTPA of R32 | ₹236.5 Cr | Internal accruals | Q3 FY27 | ₹600-825 Cr per annum |

| MPP De-bottlenecking | Dahej capacity expansion for new molecule | ₹75 Cr | Internal accruals | Q3 FY27 | ₹140-160 Cr per annum |

| Chemours Project | Commercial capacity for innovative liquid cooling product | ₹120 Cr | 35% customer funded, balance internal accruals | Q2 FY27 | Under confidentiality |

| Renewable Power Project | 14.9 MW hybrid capacity across NFIL & NFASL | ₹15.73 Cr | Investment in SPV | Not specified | Not specified |

CDMO Business Update

  • Phase I of cGMP4 capex (approved Feb '24, ₹288 Cr total) operationalized in Q3 FY26
  • Phase II cGMP4 capex of ₹125 Cr approved and expected to operationalize by Q4 FY27
  • Strategy focuses on balanced portfolio with mix of late/commercial and early-stage molecules
  • Expanding footprint in therapeutic areas: Oncology, Respiratory, Cardiovascular, Neurology, and Animal Health

Advanced Materials Initiative

  • Company is incubating a new high-growth, high-margin business vertical focused on advanced materials
  • Building on core fluorination capabilities for niche applications in Data Centers, Electronics, Defence & Semiconductors

R&D Capabilities

  • Total R&D spend in FY26: ₹48.71 Cr
  • 3 Modern R&D Centers: Surat (Gujarat), Dewas (MP), and Runcorn (Manchester)
  • Surat center: 65 chemists and 40 engineers, commercial-scale capabilities
  • Dewas and Runcorn centers: 88 total team members, focus on contract development and technology transfer

ESG Performance Highlights

  • Carbon emissions: Increased 11.1% in tCO₂/tonne of production
  • Renewable electricity usage: 12.15% in 2026
  • Workplace diversity: 3.94% in 2026
  • Gender diversity in leadership: 0% in 2026
  • Gender diversity in Board: 10%
  • Complaint resolution: 89.24% in 2026
  • Zero cases of corruption and bribery

Corporate Governance

  • Board composition includes 9 members with detailed profiles provided
  • Various committees established with majority independent directors
  • CSR spend in FY25-26: ₹8.72 Cr
  • Progressive dividend track record maintained

Upcoming Event

  • Analyst/Institutional Investor Meet scheduled for August 20, 2026, at 10:00 AM IST
  • Presentation based on publicly available information
  • Intimation also available on company website: www.nfil.in